4.7 Review

Endoplasmic Reticulum Stress-Activated Cell Reprogramming in Oncogenesis

期刊

CANCER DISCOVERY
卷 5, 期 6, 页码 586-597

出版社

AMER ASSOC CANCER RESEARCH
DOI: 10.1158/2159-8290.CD-14-1490

关键词

-

类别

资金

  1. Institut National du Cancer (INCa)
  2. Ligue Nationale Contre le Cancer (Comites des Landes)
  3. ECOS-CONICYT [C13S02]
  4. FONDECYT [1140549]
  5. Millennium Institute [P09-015-F]
  6. Ring Initiative [ACT1109]
  7. Michael J. Fox Foundation for Parkinson's Research
  8. COPEC-UC Foundation
  9. FONDEF [D11I1007]
  10. Frick Foundation
  11. Irish Cancer Society [CRS11CLE]
  12. Breast Cancer Campaign [2010NOVPR13]
  13. Belgian grants-Interuniversity Attraction Poles [IAP 7/32]
  14. [CONICYT-USA2013-0003]

向作者/读者索取更多资源

Stress induced by the accumulation of unfolded proteins in the endoplasmic reticulum (ER) is observed in many human diseases, including cancers. Cellular adaptation to ER stress is mediated by the unfolded protein response (UPR), which aims at restoring ER homeostasis. The UPR has emerged as a major pathway in remodeling cancer gene expression, thereby either preventing cell transformation or providing an advantage to transformed cells. UPR sensors are highly regulated by the formation of dynamic protein scaffolds, leading to integrated reprogramming of the cells. Herein, we describe the regulatory mechanisms underlying UPR signaling upon cell intrinsic or extrinsic challenges, and how they engage cell transformation programs and/or provide advantages to cancer cells, leading to enhanced aggressiveness or chemoresistance. We discuss the emerging crosstalk between the UPR and related metabolic processes to ensure maintenance of protein homeostasis and its impact on cell transformation and tumor growth. Significance: ER stress signaling is dysregulated in many forms of cancer and contributes to tumor growth as a survival factor, in addition to modulating other disease-associated processes, including cell migration, cell transformation, and angiogenesis. Evidence for targeting the ER stress signaling pathway as an anticancer strategy is compelling, and novel agents that selectively inhibit the UPR have demonstrated preliminary evidence of preclinical efficacy with an acceptable safety profile. (C) 2015 AACR.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据